EvaluatePharma has unveiled a new service enhancement, Tracking Drugs@FDA, which provides clients access to the entire approved FDA drugs, related FDA document library and FDA Orange Book patent data.
Tracking Drugs@FDA and Orange Book Patent Data gives analysis of FDA market intelligence, according to the company.
EvaluatePharma research head Anthony Raeside said, "Through our proprietary software platform and meticulous data standardization, Tracking Drugs@FDA finally unlocks the value of the massive FDA approval & patent datasets, whatever your area of interest might be."
The solution provides regulatory approval analysis, which includes information on FDA approved brand names, generic drugs and therapeutic biological products, reviewing labels for approved drugs, tracking generics landscape against a brand name drug.
It also provides details on active (ANDA) and tentative approvals and to know therapeutically equivalent drug products for a brand name or generic.
Tracking Drugs@FDA covers the biotechnology and pharmaceutical sectors and also features EvaluatePharma platform's ability to search, create and export reports along with managing and receiving new deeper-level data alerts via email.
